Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2649 for:    sight sciences
Previous Study | Return to List | Next Study

Use of the OMNI® Surgical System in Combination With Cataract Extraction in Open Angle Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03861169
Recruitment Status : Recruiting
First Posted : March 4, 2019
Last Update Posted : March 4, 2019
Sponsor:
Information provided by (Responsible Party):
Sight Sciences, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will prospectively assess the clinical effect of ab‐interno transluminal viscoelastic delivery and trabeculotomy performed using the OMNI Surgical System in combination with Cataract Extraction on intraocular pressure (IOP) and the use of IOP‐lowering medications in patients with mild‐moderate open angle glaucoma (OAG).

Condition or disease Intervention/treatment Phase
Open Angle Glaucoma Device: Transluminal viscoelastic delivery and trabeculotomy Not Applicable

Detailed Description:
This prospective, multicenter, single‐arm, post‐market clinical study will evaluate the impact of ab‐interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System in conjunction with cataract surgery on IOP and the use of hypotensive medications in patients with mild to moderate open angle glaucoma.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 220 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Multi‐Center, Post‐Market Study of Use of the OMNI® Surgical System in Combination With Cataract Extraction in Open Angle Glaucoma
Actual Study Start Date : February 22, 2019
Estimated Primary Completion Date : August 30, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract Glaucoma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Viscoeleastic delivery & trabeculotomy
Patients with open angle glaucoma and cataract
 Device: Transluminal viscoelastic delivery and trabeculotomy
Ab‐interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in mean unmedicated diurnal IOP [ Time Frame: 12 months ]
    Reduction in mean unmedicated diurnal IOP from baseline to 12 months

  2. Change in mean number of IOP‐lowering medications [ Time Frame: 12 months ]
    Reduction in mean number of IOP‐lowering medications from screening to 12 months


Secondary Outcome Measures :
  1. Percent of eyes with a ≥20% reduction in unmedicated diurnal IOP at 12 months [ Time Frame: 12 months ]
  2. Percent of eyes with unmedicated diurnal IOP between 6 and 18 mmHg inclusive at 12 months [ Time Frame: 12 months ]

Other Outcome Measures:
  1. Safety Endpoint- Adverse events [ Time Frame: 12 months ]
    Rates of ocular adverse events (intraoperative, postoperative)

  2. Safety Endpoint- best corrected visual acuity [ Time Frame: 12 months ]
    Reduction in best corrected visual acuity (BCVA) from baseline (note: reduction in BCVA due to PCO will not be treated as a safety event)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- (only one eye of each subject is eligible, and all ocular criteria apply to the study eye):

  1. Male or female subjects, 22 years or older.
  2. Visually significant cataract
  3. Diagnosed with mild to moderate open angle glaucoma (e.g. primary open angle glaucoma, pigmentary glaucoma, pseudoexfoliative glaucoma) per AAO/AGS/ICD‐10 Glaucoma Stage Definitions.1
  4. At screening, on 1‐3 IOP‐lowering medications2 with a medicated IOP ≤25 mmHg OR on zero (0) IOP‐lowering medications with an IOP 21‐30 mmHg.
  5. At baseline, unmedicated diurnal IOP 21‐30 mmHg and, for subjects who were medicated at screening, IOP at least 3 mmHg higher than screening IOP.
  6. Scheduled for cataract extraction followed by abinterno transluminal viscoelastic delivery and trabeculotomy using the OMNI Surgical System.
  7. Shaffer grade of ≥ III in all four quadrants
  8. Potential of good best corrected visual acuity post cataract extraction, in the investigator's judgment
  9. Able and willing to comply with the protocol, including all follow‐up visits.
  10. Understands and signs the informed consent.

Exclusion Criteria:

- (All criteria apply to the study eye; both eyes of a single subject need not be eligible):

  1. Any of the following prior treatments for glaucoma:

    • Laser trabeculoplasty ≤3 months prior to baseline
    • iStent implanted ≤6 months prior to baseline
    • Implanted with Cypass, Xen, Express, glaucoma draining device/valve, or Hydrus Device
    • Prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy, ECP or CPC
  2. Normal tension glaucoma
  3. Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma
  4. Severe glaucoma by AAO/AGS/ICD‐10 guideline
  5. Use of oral hypotensive medication treatment for glaucoma
  6. History of elevated IOP due to steroid response
  7. In the investigator's judgement, predisposed to significant risk because of washout of ocular hypotensive medications.
  8. Ocular pathology or medical condition which, in the investigator's judgment, would either place the subject at increased risk of complications, contraindicate surgery, place the subject at risk of significant vision loss during the study period (e.g., wet AMD, corneal edema, Fuch's dystrophy, etc.), or interfere with compliance to elements of the study protocol (e.g., returning to investigator's office for follow‐up visits).
  9. Participation (≤ 30 days prior to baseline) in an interventional trial which could have a potential effect on the study outcome, as determined by the study investigator.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03861169


Contacts
Layout table for location contacts
Contact: Kavita p Dhamdhere, MD, PhD 16502234062 kdhamdhere@sightsciences.com
Contact: Anne Ripley 6616458546 Anne@sightsciences.com

Locations
Layout table for location information
United States, Texas
El Paso Eye Surgeons Recruiting
El Paso, Texas, United States, 79902
Contact: Mark Gallardo, MD    915-542-0279    gallardomark@hotmail.com   
Sponsors and Collaborators
Sight Sciences, Inc.
Investigators
Layout table for investigator information
Study Director: kavita p dhamdhere, MD, PhD Sight Sciences
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Sight Sciences, Inc.
ClinicalTrials.gov Identifier: NCT03861169    
Other Study ID Numbers: 06213
First Posted: March 4, 2019    Key Record Dates
Last Update Posted: March 4, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Cataract
Glaucoma, Open-Angle
 Ocular Hypertension
Eye Diseases
Lens Diseases